A collaborative study by Chinese and U.S. researchers has for the first time identified a critical new regulator of tumor growth, metastasis and immune response, which they showed to be an effective therapeutic target for triple-negative breast cancers (TNBCs) and potentially other cancers resistant to conventional treatments.